Triple-action silver nanoparticle composite for antibacterial, antiviral, and antifungal applications

Overview

This solution is a broad-spectrum antimicrobial nanoparticle composite designed as a quaternary ammonium compound (quats)-free additive for Lysol/Dettol-style disinfectant products. It combines silver nanoparticles (AgNPs) with biocompatible stabilizers and small bioactive molecules from fungi to create a single formulation capable of fighting bacteria, viruses, and fungi at the same time. By replacing conventional quats with this nanoparticle-based approach, the technology offers a potential alternative for household and institutional disinfection products while addressing growing concerns about quats-related health and environmental effects.

Technical specifications

Core components:

• Silver nanoparticles synthesized through novel one-pot aqueous methods in biocompatible matrices
• Polymeric stabilizers including chitosan, PNIPAM, PLGA, and PMMA, with tunable co-polymer functional groups and adjustable pH and salt environments
• Non-polymeric stabilizers such as plant extracts, activated carbons, and metal-organic frameworks
• Small bioactive molecules (natural products from fungi, including compounds such as cytochalasins) screened for antibacterial, antifungal, and cytotoxic activity

Key features:

• Tunable nanoparticle size ranging from approximately 30 nanometers to 3 microns
• Demonstrated superior antibacterial activity against both Gram-positive and Gram-negative bacteria compared to common sulfa drugs and other reported silver nanoparticle compositions
• Compatibility with Lysol and Dettol product matrices as a drop-in additive
• Potential to combine with fungal-derived bioactive molecules to enhance potency across all three microbe types

Technology readiness level

The technology is at an early-to-mid stage of development. Prior work by the research team has established effective one-pot silver nanoparticle synthesis methods and demonstrated antibacterial performance superior to existing alternatives. A library of fungal-derived bioactive molecules is already available for screening. The next phase involves validating simultaneous antibacterial, antiviral, and antifungal efficacy within the specific Lysol and Dettol matrices, optimizing stabilizer chemistry as needed, and screening combinations of silver nanoparticles with fungal metabolites for enhanced potency. Further formulation work and product-level testing will be required before commercial readiness.